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Background: Phosphatase and tensin homolog (PTEN) 
hamartoma tumor syndrome (PHTS) is caused by germ 
line mutations in the PTEN gene. Symptoms include 
cancer pre- disposition, immune deviations, and 
lipomas/lipomatosis. No causal standard therapy is 
available. We describe a therapeu- tic attempt with the 
mammalian target of rapamycin (mTOR) inhibitor 
sirolimus for a PHTS patient suffering from thymus 
hyperplasia and lipomatosis. We furthermore assessed 
the in vitro effects of sirolimus and other inhibitors on 
lipoma cells of the patient. 
Methods: The patient underwent clinical and blood 
examinations and whole-body magnetic resonance 
imaging to assess tumor sizes. Lipoma cells of the patient 
were incubated with inhibitors of the phosphoinositide-
3-kinase (PI3K)/AKT/ mTOR signaling pathway to 
analyze the effects on proliferation, adipocyte 
differentiation, and survival in vitro. 
results: Sirolimus treatment improved somatic growth 
and 
reduced thymus volume. These effects diminished over 
the treatment period of 19 mo. Sirolimus decreased 
lipoma cell proliferation and adipocyte differentiation 
in vitro but did not cause apoptosis. PI3K and AKT 
inhibitors induced apoptosis significantly. 
conclusion: Sirolimus treatment led to an improvement 
of the patient’s clinical status and a transient reduction 
of the thymus. Our in vitro findings point to PI3K and 
AKT inhibitors as potential treatment options for 
patients with severe forms of PHTS. 
 
 
 
Phosphatase  and  tensin  homolog  (PTEN)  
dephosphorylates phosphatidylinositol-3,4,5-
triphosphate in the phosphoinositide   3-kinase   
(PI3K)/AKT/mammalian   target   of rapamycin 
(mTOR) signaling pathway. Germ line mutations 
in PTEN cause disorders, variable in severity and 
progression of symptoms—summarized as PTEN 
hamartoma tumor syndrome (PHTS) (1). The true 
prevalence is unknown but is estimated to be 1 in 
200,000–250,000 (2) for Cowden syndrome, a subtype of 
PHTS. Patients develop hamartomatous tumors, intestinal 
polyposis, vascular malformations, and lipomas and have an 
increased life-time risk for breast, thyroid, and endometrial 
cancers (3,4). The first reported successful treatment attempt 
with the mTOR complex 1 (mTORC-1) inhibitor sirolimus 
for a patient with PHTS described a reduction of tumor 
masses and improvement of the patient’s general state (5). 
More recently, an experimental oral sirolimus treatment of 
vascular malformation in a patient with PHTS, subtype 
Bannayan–Riley–Ruvalcaba Syndrome, was reported (6). 
We here describe the case of a child with an extreme 
phenotype of PHTS, including lipomatosis and severe 
cachexia. An individualized sirolimus treatment resulted in 
an improvement of the patient’s symptoms. In vitro findings 
supported the treatment efficacy. However, after 19 mo of 
treatment, tumor growth accelerated again, indicating 
adaptation of tumor cells to mTORC-1 inhibition. 
 
RESULTS 
Clinical Findings 
The patient was born as the third child of nonconsanguineous 
parents without a relevant family history. After birth, the 
patient presented as a healthy child (length: 55 cm, >90th 
percentile; weight: 3,900 g, >85th percentile; and head 
circumference: 39 cm, >97th percentile). However, the 
patient’s state worsened into severe cachexia, with complete 
loss of subcutaneous adipose tissue (Figure 1a,b). A fasting 
glucose level of 
1.9 mmol/l (35 mg/dl; reference: 3.6–5.6 mmol/l) was detected 
at the age of 42 mo. Attempts of oral hypercaloric nutrition 
failed. Parents refused nasogastric feeding. The patient’s 
growth rate slowed down to a complete growth arrest in his 
fourth year (Figure 2d,e). At the age of 6 mo, he presented with 
dysphagia and episodes of shortness of breath due to 
hyperplastic tonsils and an enlarged thymus. The thymus was 
histologically characterized by lymphoid hyperplasia with 
large fractions of fatty streaks. A colonoscopy revealed an 
intestinal lymphoid hyperplasia (7). Furthermore, abdominal 
lipomatosis, fatty infiltrations of the back muscles and the 
upper leg, and multiple solitary lipomas were observed. 
Histology 
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Figure 1.  Clinical presentation of a boy with phosphatase and tensin homolog hamartoma tumor syndrome (PHTS). (a) The photograph shows the patient at 
the age of 3 years with cachexia and the protruded abdomen. (b) Retroperitoneal fat masses are apparent in the magnetic resonance imaging (MRI). 
(c) Regions of interest of the lipoma at the neck (red), the hyperplastic thymus (green), and the abdominal lipomatosis (blue) were marked in a 
threedimensional reconstruction of an MRI and (d) quantified as shown in the graphs to monitor tumor growth. (e–h) The enlarged thymus (marked with a 
white plus) shrank during the first 4 mo of sirolimus treatment (ST) and increased in size after 19 mo and further after cessation of therapy. (i–l) The 
abdominal lipomatosis did not decrease in size until the 19th mo of sirolimus therapy. (m–p) The solitary lipomas, e.g., at the right neck, did not change in 
volume. The shaded area on the time line indicates the duration of sirolimus treatment. Parental consent to publish this photograph was obtained by the 
authors.
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Figure 2. Serum markers and growth charts. (a–c) Serum levels of leptin, adiponectin, and insulin-like growth factor binding protein (IGFBP)-2 were 
measured before, during, and after sirolimus treatment. The dotted lines indicate the reference intervals. (d,e) Growth charts show the stagnated weight 
and the catch-up growth after initiation of sirolimus therapy. The patient’s weight increased slightly during treatment. p3, 3rd percentile; 
p5, 5th percentile; p95, 95th percentile; p97, 97th percentile. #The open circle indicates a measurement with a concentration higher than the detectable 
limit, >1,680 ng/ml; the shaded areas indicate the duration of sirolimus treatment. 
 
revealed that the benign fatty tumors were composed of about 
80% white adipocytes with insular spots of multilocular cells, 
appearing as brown adipocytes. Subsequently, the tumors grew 
progressively, and additional lipomatous swellings under the 
skin appeared. Volumes of the tumor masses at the age of 42 
mo are illustrated in the three-dimensional reconstruction of a 
magnetic resonance image (Figure 1c,d and Supplementary 
Video S1 online). 
Sanger sequencing of PTEN revealed no point mutations in 
the exons and flanking regions. However, a large 
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heterozygous PTEN deletion of the exons 2–9 of the 
nine exons was discovered in the patient’s peripheral 
blood cells, cultured fibroblasts, and cultured lipoma 
cells using multiplex ligation-dependent probe 
amplification. The parents and siblings tested 
negative for the deletion. Further investigations via 
microarray-based comparative genomic  
hybridization  revealed  the  deletion to be located 
between positions chr10:89,629,799 bp and 
chr10:89,781,899 bp. Exons 2–9 of the PTEN gene 
and about 53,400 bp downstream of the PTEN gene 
were found to be deleted. 
 
Effects of Sirolimus Treatment 
The abdominal lipomatosis led increasingly to severe 
compromise of mobility and breathing. Surgical lipoma 
reduction and chemotherapy were not justified due to the 
clinical state of the child. Given the published case of 
successful sirolimus treatment for Proteus syndrome (5), the 
known dose and safety profile, and the plausible mechanism of 
blocking being increased PI3K signaling downstream of 
PTEN, an individualized therapy attempt with sirolimus was 
initiated at the ageof 46 mo. The patient received a daily oral 
sirolimus dose of 
0.1 mg/kg body weight. Aimed serum levels (5–10 ng/ml) were 
reached and monitored at regular intervals. 
After 4 wk of sirolimus therapy without side effects, the 
parents reported subjective improvement of physical and 
mental activity. Although serum levels of human insulin-like 
growth factor (IGF)-I (20.8, 14.1–34.3, and −3.33 µg/l 
(median, range, and mean SD score, respectively) and IGF-
binding protein (IGFBP)-3 (0.32, 0.22–0.56, −8.27 µg/l) 
remained lower than age-matched reference values before 
and during sirolimus therapy, a catch-up growth of 4.8 cm 
(±0.57 SD score) was determined during the first 4 mo of 
therapy (Figure 2d). After 1 y of treatment, the patient was 
able to walk and to attend kindergarten. However, the catch-
up growth slowed down. A whole-body magnetic resonance 
imaging conducted after 4 mo of treatment revealed a 
regression of the thymus (7). We measured a reduction of 
thymus size from 246 to 99 cm3. The changes in the subsets 
of blood lymphocytes under therapy were reported earlier 
(7). Another whole-body magnetic resonance imaging 
(MRI) after 19 mo of sirolimus therapy showed recurrent 
growth of the thymus up to the size before therapy (273 cm3; 
Figure 1e–g). The intestinal mucosa–associated lymphatic 
tissue hyperplasia improved under therapy. The growth of 
the abdominal lipomatosis was attenuated when comparing 
the 4-mo period before and after initiation of sirolimus 
therapy (MRI1 → MRI2, from 1,901 to 2,311 cm3; Δ410 cm3) 
with the last 15 mo of treatment (MRI2 → MRI3, from 2,311 
to 2,471 cm3; Δ160 cm3, Figure 1i–k). The lipoma at the neck 
showed no significant changes in volume over the observed 
time course (Figure 1d,m–p). The lack of subcutaneous 
adipose tissue of the patient persisted, and body weight 
slightly increased by only 750 g. Sirolimus administration was 
stopped after 19 mo due to the absence of clinical benefit. 
Another MRI was conducted 8 mo after cessation of the 
sirolimus treatment. The thymus volume increased further up 
to 376 cm3 (Figure 1d,h), but no further growth of the 
abdominal lipomatosis was found (Figure 1d,l). 
Leptin and adiponectin serum levels were measured during 
sirolimus treatment. Interestingly, the high leptin levels 
decreased from 2.9 to 1.1 ng/ml (reference: 0.2–1.19 µg/l, 5th– 
95th percentile range) after the start of therapy but increased 
subsequently up to values measured initially—and greater— 
after treatment cessation (Figure 2a). Adiponectin levels 
increased under sirolimus treatment and persisted at median 
values of 25.7 (range: 22.5–30.0 µg/ml) within the upper range 
of the reference interval (2.33–26.50 µg/ml, 5th–95th percentile 
range). After cessation of sirolimus treatment, the values 
decreased to initial levels (Figure 2b). IGFBP-2 has been 
proposed as a diagnostic marker for the success of sirolimus 
therapy (5). To verify this, IGFBP-2 concentrations were 
measured in serum samples taken at every consultation of the 
patient. IGFBP-2 levels were highly variable and elevated 
compared with reference values (277–640 ng/ml, 5th–95th 
percentile range). However, no statistically significant difference 
between the concentrations before and under sirolimus 
therapy was found (Figure 2c). 
 
Effects of Sirolimus In Vitro 
We tested the effects of sirolimus, everolimus, and 
temsirolimus on proliferation, apoptosis, and terminal adipose 
differentiation of lipoma cells in vitro. Viability assays 
revealed a 
42.5 ± 3.7% decrease of viability after 96 h of sirolimus 
treatment (100 nmol/l). Everolimus and temsirolimus showed 
lower effects at equimolar concentrations (Figure 3a). 
Furthermore, sirolimus caused a significant inhibition of 
adipose differentiation by 56.4 ± 9.1% (P < 0.01) at 100 nmol/l 
(Figure 3b). We found no evidence for an apoptotic/cytotoxic 
effect of sirolimus (Figure 3c) or its analogues (Table 1). 
Western blots revealed a decreased phosphorylation of the 
mTORC-1 target p70S6 kinase (p70S6K) after 48 h of 
sirolimus preincubation followed by stimulation with IGF-I. 
Under the same conditions, decreased levels of 
phospho(S636/639) insulin receptor substrate 1 (IRS1) and 
increased levels of phospho(S473 and T308) AKT were 
observed (Figure 3e), indicating that the feedback inhibition of 
AKT mediated by mTORC-1, p70S6K, and IRS1 was 
attenuated by sirolimus (8). 
 
Other Inhibitors of the PI3K/AKT/mTOR Pathway 
Because preferential mTORC-1 inhibitors did not induce 
apoptosis of lipoma cells in vitro, we tested other inhibitors 
of the PI3K/AKT/mTOR pathway. An overview is given in 
Table 1. The mTORC-1/-2 inhibitors WYE-354 (9) and KU-
0063794 (10) suppressed lipoma cell viability by 76.1 ± 1.8 and 
75.8 ± 0.1%, respectively, but did not induce apoptosis. The 
combined mTORC1/2 and PI3K inhibitor NVP-BEZ235 
(11) showed similar effects. In contrast, apoptosis was induced 
by the PI3K inhibitor LY294002 by 74.2 ± 5.2%. Perifosine, 
an AKT inhibitor, decreased viability almost completely by 
96.4 ± 0.6% and increased the number of apoptotic lipoma cells 
by 84.5 ± 0.9% (Figure 3d). 
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DISCUSSION 
The clinical management of PHTS is restricted to genetic 
counseling, surveillance for malignancies, and surgical 
interventions (12,13). A causal pharmacological therapy could 
be based on functional compensation of the dysregulated 
PTEN/ AKT/mTOR signaling pathway. Two successful 
attempts of oral treatment with the mTORC-1 inhibitor 
sirolimus for patients with PTEN mutations have been reported 
(5,6). The treatment attempt described here was the first PHTS 
case in which lipoma adipocytes were the focus of treatment, 
whereas other cell types, e.g., endothelial cells, were targeted 
in other patients (6). Under sirolimus therapy, the growth of the 
patient’s abdominal lipomatosis was attenuated, but the tumor 
volume was not reduced. These findings are in line with another 
case of successful sirolimus treatment for a child with a PTEN 
mutation, in which no changes in fatty tumor masses or 
subcutaneous adipose tissue were reported (5). We do not have 
clear evidence that sirolimus treatment did affect the patient’s 
lipomatosis because the lipomatosis did not increase in size 
again after cessation of the sirolimus treatment. The 
attenuation of lipoma growth could have been simply an 
expression for the tragic state of cachexia in the patient, 
inhibiting further growth of the lipomas. In contrast, the 
decrease of the thymus volume under sirolimus therapy and 
the regrowth after cessation of treatment indicate convincingly 
a beneficial effect of sirolimus for the patient. The recurrence 
of the hyperplastic thymus after 19 mo of sirolimus therapy 
might be due to an acquired resistance, as has been reported 
before for patients treated with sirolimus analogues (14). 
Different mechanisms, such as hyperactivation of the AKT 
(14) or of the mitogen-activated protein kinase (MAPK) 
pathway (15) could be responsible for the potential resistance. 
Marsh et al. (5) reported decreased IGFBP-2 serum levels 
under sirolimus therapy of a patient with PHTS and reelevation 
during cessation of therapy for 12 wk. We suspect the high 
IGFBP-2 levels in our patient to be an indicator of the severe 
state of cachexia or the decreased PTEN activity, as proposed 
elsewhere (16), rather than being a disease marker. Lowered 
leptin serum levels, as seen in our patient, might be a more 
relevant marker for therapy success in patients with PHTS pre- 
senting with fat-containing tumors. 
When studying the effects of sirolimus in vitro in preadipo- 
cytes derived from a lipoma of the patient, we found a signifi ant 
decrease of viability and terminal adipose differentiation under 
sirolimus treatment in vitro already at concentrations (10 nmol/l) 
comparable with therapeutic serum levels of the patient. In con- 
trast with our results, other groups reported apoptotic effects 
of sirolimus on tumor cells with defi      t p53 or p21 function 
(17) or at micromolar concentrations (18). Analysis of pathway 
activation after treatment with sirolimus revealed an attenuated 
activation of the mTORC-1 target p70S6K, which is in line with 
the observed antiproliferative effect of sirolimus on the lipoma 
cells. Interestingly, after 48-h treatment with sirolimus, we found 
decreased IRS1 serine phosphorylation and a concomitantly 
increased  AKT  phosphorylation.  Th s  AKT  hyperactivation 
(14) could be a possible mechanistic explanation for the siroli- 
mus resistance observed in our patient. We have to acknowledge 
that a limitation of our in vitro studies is the lack of age- and 
sex-matched healthy control preadipocytes to estimate the effect of 
the inhibitors on normal adipose tissues. 
We screened additional inhibitors of the PI3K/AKT/mTOR 
pathway (Table 1) to identify putative pharmacological tar- 
gets for the efficient induction of apoptosis in lipoma cells. 
Although  long-term  incubation  with  sirolimus  was  shown to 
exert inhibitory effects on mTORC-2 also (19), treatment with 
mTORC-1/-2 inhibitors led to a stronger decrease in the 
viability of lipoma cells. The observed proapoptotic effects of 
perifosine (AKT inhibitor) and LY294002 (PI3K inhibitor) 
on lipoma cells could be mediated by a negative regulation of 
the Forkhead transcription factor Foxo1 on phosphoryla- tion 
by AKT (20). Inhibition of PI3K/AKT might represent a future 
treatment option for lipomatosis linked with defects in the 
PTEN gene. Limited potentially beneficial effects of peri- fosine 
treatment for colorectal cancer and multiple myeloma were 
reported (21). Nevertheless, grades 3–4 adverse effects (e.g., 
anemia, hand–foot syndrome, or pulmonary embolism) (21,22) 
limit the clinical applicability of perifosine. 
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table 1. Effects of inhibitors on proliferation and apoptosis of lipoma cells in culture 
 
 
Maximum inhibition 
Drug (concentration of maximum 
  of viability (%)  Change in apoptotic cells (%)   
 
inhibition) Target (mean ± SEM) (mean ± SEM) Human trials 
Sirolimus (100 nmol/l) mTORC-1 42.50 ± 3.67** No Approved 
Everolimus (10 nmol/l) mTORC-1 30.71 ± 2.55** No Approved 
Temsirolimus (100 nmol/l) mTORC-1 25.82 ± 4.88* No Approved 
WYE-354 (5 µmol/l) mTORC-1 + 2 76.10 ± 1.83** No Preclinical (25) 
KU-0063794 (5 µmol/l) mTORC-1 + 2 75.80 ± 0.06** No Preclinical (25) 
Wortmannin (100 µmol/l) PI3K 40.89 ± 3.24** No — 
LY294002 (500 µmol/l) PI3K 98.09 ± 0.70** 74.22 ± 5.21** — 
NVP-BEZ235 (10 µmol/l) PI3K, mTORC-1 + 2 82.12 ± 4.12** No Phase I/II (26) 
Perifosine (100 µmol/l) AKT 96.40 ± 0.60** 84.52 ± 0.90** Phase III (27) 
The presented data show the effects of inhibitors of the PI3K/AKT/mTOR signaling pathways on proliferation and apoptosis of the lipoma cell strain in vitro. Data of 
three independent experiments (WST-1 assays) in triplicates are shown. Apoptotic effects were assessed for the agents with a significant antiproliferative effect in 
three independent experiments in duplicates. 
mTORC, mammalian target of rapamycin complex; PI3K, phosphoinositide-3-kinase. 
*P < 0.01; **P < 0.001. 
 
METHODS 
Consent and Ethics 
Written informed consent of the parents was obtained for the culture 
of lipoma cells, collection, and presentation of clinical data as well as 
for sirolimus treatment. Ethics consent for sirolimus treatment was 
obtained from the internal review board of the Leipzig University 
Hospital. 
Genotyping 
DNA was extracted using the FlexiGene DNA isolation kit (Qiagen, 
Hilden, Germany). Exons and flanking regions of PTEN (GenBank: 
NT_030059; NM_000314.4) were amplified by polymerase chain 
reaction and analyzed by direct DNA sequencing with the Mutation 
Surveyor V3.97 (SoftgeneticsLLC, State College, PA). To detect dele- 
tions/duplications of exons of PTEN, multiplex ligation-dependent 
probe amplification screening was performed (MRC-Holland, 
Amsterdam, The Netherlands). Break point analysis was performed 
using a custom-designed array-based comparative genomic hybrid- 
ization of chromosome 10 (Source Bioscience, NimbleGen platform, 
Nottingham, UK). Further details of the method will be given on 
request. 
MRI Reconstruction 
MRI data (sequence = T1-turbo-spin-echo, echo time (TE) = 9.5 ms, 
repetition time (TR) = 670 ms, device: 3 tesla; Siemens, Erlangen, 
Germany) were assessed using the open source software Osirix- 
DICOM    viewer     (http://www.osirix-viewer.com/Contact.html). 
We  used  two-dimensional-growing  brush  regions  of  interest  for 
segmentation of the tumor volumes (23). Volumes were segmented 
twice by two observers and presented as means ± SDs. The volume 
rendering of the MRI analysis differed slightly from routine measure- 
ments reported earlier (7). 
Primary Cell Culture 
Lipomas from the lumbar skin and retroperitoneal space were 
resected for diagnostic purposes. Remaining tissue was used to estab- 
lish an adherent preadipocyte culture. A detailed protocol is given in 
the Supplementary Data online. 
Adipose Differentiation 
Lipoma cells were differentiated following adapted protocols (24). 
Sirolimus was added at the indicated concentrations. To determine 
the percentage of lipid-accumulating cells, triglycerides were stained 
with Nile red and Hoechst-33342 (both reagents from Sigma, Munich, 
Germany) counterstaining visualized the nuclei. Five defined, ran- 
domly chosen areas per well were counted using fluorescence micros- 
copy. A detailed protocol is given in the Supplementary Data online. 
Western Blots 
To investigate the effect of sirolimus on the activity of mTORC-1 in 
vitro, lipoma cells were incubated with sirolimus for 48 h and sub- 
sequently stimulated with recombinant human IGF-I (Pharmacia, 
Uppsala, Sweden) for 15 min. After lysis, electrophoretic separation of  
proteins,  and  blotting  onto  nitrocellulose  membranes,  immu- 
noblotting was performed to detect the amount of phosphorylated 
p70S6K(Thr421/Ser424),   IRS1(Ser636/639),   and   AKT(Thr308; 
Ser473; all from NEB, Ipswich, MA) using standard protocols. 
Cell Proliferation 
The effects of the inhibitors on cell proliferation were estimated 
using the WST-1 assay (Roche, Mannheim, Germany) following the 
manufacturer’s instructions. Cells were seeded at a density of 10,000 
cells/cm2 and incubated for 72 or 96 h with different inhibitor con- 
centrations. The following inhibitors were used: sirolimus, everoli- 
mus, temsirolimus, wortmannin, NVP-BEZ235 (LCLaboratories, 
Woburn, MA), perifosine, LY294002 (Selleckchem, Munich, 
Germany), WYE-354, and KU-0063794 (Chemdea, Rigdewood, NJ). 
Absorbance was measured at 450 nm. 
Induction of Apoptosis and Cell Death 
Apoptosis was determined by annexinV–fluorescein isothiocyanate/ 
propidium iodide  (BD,  Franklin  Lakes,  NJ)  staining.  Cells  were 
seeded at a density of 5,000 cells/cm2 in 35-mm dishes. After 24 h, 
cells were treated with inhibitors for 72 h. Media were changed every 
day. Cells were trypsinized and incubated with annexinV–fluorescein 
isothiocyanate and propidium iodide for 10 min at 4 °C in the dark. 
AnnexinV-positive and AnnexinV/propidium iodide–double posi- tive 
cells were considered apoptotic/dead. 
Measurement of IGFBP-2, IGFBP-3, Leptin, and Adiponectin 
Serum levels of IGFBP-2, IGFBP-3, leptin, and adiponectin were deter- 
mined using the IGFBP-2 enzyme immunoassay, IGFBP-3 enzyme- 
linked  immunosorbent  assay,  the  sensitive  leptin  enzyme-linked 
immunosorbent assay, and the adiponectin enzyme immunoassay 
(Mediagnost,  Reutlingen,  Germany)  according  to  manufacturer’s 
instructions. Age or age- and BMI-dependent reference intervals 
were transferred from manufacturer’s data. 
Statistics 
Statistical  analysis  of  data  was  performed  with  GraphPad  Prism 
5.4 software (GraphPad Software, La Jolla, CA) by applying one- 
way ANOVA, followed by Bonferroni’s multiple comparison test. 
Significant differences are designated as *P < 0.01; **P < 0.001. 
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